Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies
– Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 –
– Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 –
– Phase 2b data for the prevention of Basal Cell Carcinomas in patients with Gorlin Syndrome anticipated 2Q 2023 –